secwatch.observer — SEC 8-K summary
======================================

Issuer:     enGene Therapeutics Inc. (ENGN)
CIK:        0001980845
Form:       8-K
Filed at:   2026-04-09T23:59:59+00:00
Accession:  0001193125-26-149597
Event type: other_material
Sentiment:  positive
Materiality: 0.45
Item codes: 5.03, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

enGene Holdings changes name to enGene Therapeutics Inc., signals commercial readiness for detalimogene
--------------------------------------------------------------------------------

- Name change to enGene Therapeutics Inc. effective April 8, 2026; tickers ENGN/ENGNW unchanged.
- BLA submission for detalimogene planned for 2H 2026 in BCG-unresponsive NMIBC with CIS.
- Potential approval and commercial launch targeted for 2027.
- New CUSIP numbers: common shares 29286X101, warrants 29286X119.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1980845/000119312526149597/0001193125-26-149597-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1980845/000119312526149597/engn-20260407.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-149597

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer